Table 3.
Expression levels in RCC of patients with/without development of metastatic disease
| Metastatic disease | Relapse-free disease | p-value | |
|---|---|---|---|
| n = 15 | n = 23 | ||
| miRNA-155 | 6.07* | 15.58 | 0.095 |
| 1.80-21.03** | 7.29-27.58 | ||
| miRNA-141 | 0.072 | 0.102 | 0.682 |
| 0.033-0.671 | 0.046-0.181 | ||
| miRNA-210 | 36.758 | 41.137 | 0.317 |
| 12.147-62.417 | 28.581-82.332 | ||
| miRNA-200c | 0.266 | 0.301 | 0.502 |
| 0.108-0.487 | 0.185-0.517 | ||
| miRNA-106a | 14.522 | 25.126 | 0.081 |
| 12.469-24.862 | 16.923-42.519 | ||
| miRNA-106b | 10.387 | 16.451 | 0.030 |
| 6.591-15.950 | 11.119-25.831 | ||
| miRNA-200b | 6.556 | 7.804 | 0.87 |
| 3.849-14.096 | 3.697-14.676 | ||
| miRNA-182 | 0.302 | 0.081 | 0.194 |
| 0.051-0.728 | 0.036-0.321 |
* Medians of expression level related to RNU6B with **25th and 75th percentiles.